Inhibikase Therapeutics, Inc. (IKT) Free Cash Flow by Year
Inhibikase Therapeutics, Inc. recorded an outflow of $27.8M in free cash flow in fiscal year 2025. This represents a decrease of 45.2% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to an outflow of $42.6M in free cash flow. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Inhibikase Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
IKT Free Cash Flow by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
IKT Free Cash Flow by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What free cash flow means
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper.
More Inhibikase Therapeutics, Inc. financials
Frequently Asked Questions
What was Inhibikase Therapeutics, Inc.'s free cash flow in fiscal year 2025?
Inhibikase Therapeutics, Inc. recorded an outflow of $27.8M in free cash flow in fiscal year 2025.
How fast is Inhibikase Therapeutics, Inc.'s free cash flow growing?
Inhibikase Therapeutics, Inc. (IKT) free cash flow fell by 45.2% year over year, from -$19.1M to -$27.8M in fiscal year 2025.
What is Inhibikase Therapeutics, Inc.'s free cash flow over the last twelve months?
Inhibikase Therapeutics, Inc. (IKT) reported an outflow of $42.6M in free cash flow over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
What was Inhibikase Therapeutics, Inc.'s free cash flow in the most recent quarter?
Inhibikase Therapeutics, Inc. (IKT) reported -$12.4M in free cash flow in Q2 2026. This represents a decrease of 123.2% from the same quarter a year earlier.
What does free cash flow mean on a financial statement?
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper. This page lists what Inhibikase Therapeutics, Inc. (IKT) reported on that line in every period on record.